Circular RNA-based HPV16 therapeutic vaccine elicits potent and durable antitumor immunity
The present study results demonstrate that LNP-circRNA<sup>E7E6</sup> vaccine is capable of eliciting robust anti-tumor immunity in the periphery and TME, highlighting the potential for treating HPV16-related cancers and preventing tumor recurrence.
Authors
- Minliang Zhu
- Rong Zhou (ORCID: https://orcid.org/0000-0002-7740-5378)
- Jing Zeng (ORCID: https://orcid.org/0000-0002-4886-5682)
- Chonghui Li
- Lu Gao
- Lifang Cui
- Leshi Li
- Kunlun Xiang
- Yin Rong
Institutions
- Shenzhen Metro (China) (CN)
- Shanghai Construction Group (China) (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1186/s13046-026-03640-7
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00